Hematopoietic Stem Cell Transplant (HSCT)-Associated Microangiopathy (TAM) is a microangiopathic hemolytic anemia seen in a patient following a HSCT. This condition has a high mortality rate, many patients dying within 3 months of diagnosis.


Risk factors:

(1) female gender

(2) transplant from an unrelated donor

(3) presence of graft-vs-host disease (GVHD)

(4) infection with a fungus or virus

(5) therapy with cyclosporine A

(6) therapy with sirolimus



• Therapy with cyclosporine A or sirolimus is related to GVHD.


To read more or access our algorithms and calculators, please log in or register.